BRAF and intrahepatic cholangiocarcinoma: In the clinical trial that compared the checkpoint inhibitor pembrolizumab to investigator choice chemotherapy (ICC) in patient’s refractory to ipilimumab or to prior BRAF-targeted therapy, pembrolizumab was superior to ICC with respect to PFS and tolerability, providing the basis for accelerated approval in advanced melanoma [27].